background: For decades androgens have been considered detrimental to follicle maturation. Animal studies now suggest that they are essential for normal folliculogenesis. Especially in women with premature ovarian aging (POA), recent IVF data in humans are supportive. The literature also suggests an association between recently reported ovarian genotypes of the FMR1 gene and ovarian aging patterns. We, therefore, attempted to determine a potential difference in androgen concentrations and androgen interactions in women with POA who do or do not become pregnant while undergoing androgen supplementation, and whether androgen concentrations and pregnancy chances are affected by FMR1 genotypes. methods: We longitudinally assessed androgen metabolism in 91 women with POA, following pre-supplementation with micronized dehydroepiandrosterone (DHEA) prior to IVF. IVF outcomes were assessed based on androgen levels and ovarian FMR1 genotypes.
Introduction
Follicle maturation requires that the ovary converts from androgen dominance to an estrogen-dependent microenvironment (Aerts and Bols, 2010) . For decades androgens have, therefore, been considered detrimental to follicle maturation (Dumesic and Abbott, 2008) . More recently developed evidence, however, suggests that androgens may, indeed, be essential to normal folliculogenesis and female fertility (Gleicher et al., 2011a,b,c) . At least in mice these effects appear androgen receptor (AR)-mediated and granulosa cell-specific (Li et al., 2009) .
In 2000, Casson et al. (2000) reported improved ovarian responsiveness after dehydroepiandrosterone (DHEA) supplementation in a case series of five poor responders undergoing gonadotrophin stimulation and consecutive intrauterine insemination. A number of years ago, our center introduced DHEA supplementation into IVF of women with premature ovarian aging (POA; Barad and Gleicher, 2006) . Since then, several investigators including our group have addressed the effects of DHEA or transdermal testosterone on pregnancy and miscarriage rates in poor responders (Barad et al., 2007a,b; Gleicher et al., 2009a,b; Gleicher et al., 2010a,b,c,d; Wiser et al., 2010; Sunkara and Coomarasamy, 2011; Bosdou et al., 2012) . Although most studies suggest a beneficial effect of DHEA on fertility in POA, results are sometimes discordant. The apparent contradiction between the results of published studies may in part depend on the small numbers of patients included and in part on the heterogeneity of the patients included.
How DHEA exerts fertility-promoting effects is still unknown (Casson et al., 2000) . It is a mild androgen that gradually declines with advancing female age (Genazzani et al., 2011) . Within the ovary, it serves as a precursor for the production of androstenedione, testosterone and, consequently, estrogen (Gleicher et al., 2011a,b, c) .
As an essential substrate for steroidogenesis, one might assume that DHEA deficiency, by itself, may be the cause of impaired sustained follicular growth and development. However, not all women with POA benefit from DHEA supplementation (Gleicher et al., 2010a,b,c,d) .
The reason for the selective beneficial effect of DHEA in POA is unknown, but may depend on differences in androgen metabolism. It would be useful in clinical practice to identify predictive phenotypical parameters for improvements of functional ovarian reserve (FOR) after DHEA supplementation in women with POA. Recent investigations suggest that how the functional ovarian reserve of a woman declines with advancing age is, at least partially, dependent on ovarian genotypes and subgenotypes of the FMR1 gene (Gleicher et al., 2011a,b,c) . It is, therefore, tempting to hypothesize that potential androgen effects on follicle maturation may vary between different FMR1 genotypes and subgenotypes. This retrospective study was designed to test the hypothesis that women with POA supplemented with DHEA display different androgen metabolism depending on their FMR1 genotypes and subgenotypes, with implications for their pregnancy potential.
Materials and Methods
This study investigated 91 consecutive infertility patients, undergoing first IVF cycles between February 2010 and July 2011, coded in our center's anonymized research database as suffering from POA (Barad et al., 2007a (Barad et al., ,b, 2011 Ferraretti et al., 2011) .
A diagnosis of POA was established if women presented with abnormally elevated age-specific baseline FSH and/or abnormally low age-specific anti-Müllerian hormone (AMH) levels. Normal age-specific hormone levels were defined at all ages, as previously reported in detail (Barad et al., 2007a (Barad et al., ,b, 2011 . There were 45 women who presented with POA as the sole diagnosis; the remainder had the following additional factors: male factor (n ¼ 21), endometriosis (n ¼ 3), polycystic ovarian syndrome (n ¼ 7), tubal factor (n ¼ 14) and uterine factor (n ¼ 9).
For ovarian stimulation for IVF, a microdose agonist protocol (leuprolide acetate, Lupron w , Abbott Laboratories, North Chicago, IL, USA) was used with a daily gonadotrophin dosage of 600 IU, with a 3:1 FSH over hMG preponderance (gonadotrophin manufacturers varied, depending on patient preference; Barad and Gleicher, 2005) . Oocyte retrieval was performed in women who presented with at least one follicle of at least 18mm diameter. All oocytes that were retrieved, independent of maturity and perceived quality, were considered in determining oocyte yields as a representation of functional ovarian reserve (Monget et al., 2012) . Clinical pregnancy was considered established after a positive serum pregnancy test and observation of a gestational sac with fetal heart on vaginal ultrasound.
All women included in this study received supplementation with 25 mg of micronized DHEA, TID, for at least 6 weeks prior to initiation of IVF as the center's routine co-treatment for women suffering from POA (Barad and Gleicher, 2006; Gleicher et al., 2010a,b,c,d) . To assess the impact of androgen concentrations, and androgen interactions (as a reflection of androgen metabolism) on pregnancy potential in our study population, serum DHEA levels, DHEA sulfate (DHEA-S), total testosterone (total T) and free testosterone (free T) concentrations were measured at the beginning of DHEA supplementation (i.e. as a baseline measurement) and monthly at cycle days 2/3 until the start of the IVF cycle. Androgen measurements were performed with liquid chromatography/tandem mass spectrometry (LC/MS-MS), as reported elsewhere in detail (Shackleton, 2010) .
To assess the effects of androgen metabolism, the impact of total androgen concentrations and interactions between androgens (i.e. between DHEA, DHEA-S, total and free T) on pregnancy rates were determined by logistic regression. For this analysis, we used androgen serum levels at three time points: at the beginning of DHEA usage, during work-up for IVF and at the IVF cycle start point. As the baseline androgen levels, blood draws within the first 2 weeks of DHEA supplementation (median duration on DHEA 0.1 weeks) were utilized. For the intermediate assessment, we used blood draws that were taken within the first 8 weeks of DHEA usage (median: 7.3 weeks). Blood draws at the start of the cycle were performed at a median DHEA supplementation of 13.4 weeks. In women, who had started DHEA supplementation prior to the study period, only androgen levels during DHEA usage and at the start of the IVF cycle were analyzed.
FMR1 genotypes were assigned based on a previously reported normal range of 26 -34 (median 30) CGG repeats according to the Gauss distribution (Wittenberger et al., 2007) : normal was defined by both alleles within the range of 26-34 CGG repeats, while abnormal was defined by the presence of one or both alleles above or below the normal range of 26 -34 CGG repeats (Gleicher et al., 2009a (Gleicher et al., ,b, 2010a .
First, non-parametric tests (Mann -Whitney U-tests and x 2 ) were performed to assess potential confounding factors of pregnancy. These included female age, body mass index (BMI), FMR1 genotypes and subgenotypes, additional indications for fertility treatment, duration of DHEA supplementation, total gonadotrophin dosage used and the number of oocytes retrieved and embryos transferred. Only age and the number of retrieved oocytes and embryos transferred were significantly associated with pregnancy potential.
Consequently, the impact of total androgen concentrations and interactions between androgens and pregnancy were assessed in two steps: first, by regression analyses that were adjusted for DHEA supplementation length to alleviate potential confounding effects from variable DHEA supplementation periods. Secondly, those androgens/androgen interactions that proved significant were then further included in multivariate regression models, adjusted for DHEA supplementation length, age and number of oocytes retrieved.
Statistical analysis was undertaken using SPSS 18.0 (SPSS, Chicago, IL, USA). Baseline characteristics of patients were compared using t-tests. Continuous values are presented as the mean + SD. Outcome parameters are presented as proportions. A P-value , 0.05 was considered statistically significant.
The presented data only involved retrospective reviews of medical records and an anonymized electronic research database. Patients at our center sign an informed consent at initial consultation, which allows for such reviews if the patient's medical record remains confidential and her identity is protected. These conditions were met in this case, allowing for expedited approval by the Institutional Review Board of the Center for Human Reproduction.
Results
The study group presented with a mean age of 39.8 + 4.4 years (29.7% were ≤38 years); the mean baseline FSH was 10.3 + 4.5 mIU/ml and the mean AMH was 1.4 + 1.9 ng/ml ( Table I ). Out of 91 IVF patients with POA, 23 women achieved a clinical pregnancy; 4 of these miscarried and 19 had a live birth (clinical pregnancy rate 25.3%; live birth rate 21%). Androgen concentrations did not differ among the subgroups of women with additional infertility diagnoses, though the seven patients who also suffered from PCOS showed a trend towards higher baseline AMH and androgen concentrations.
After adjustments for age, duration of DHEA supplementation and number of oocytes retrieved, total androgen concentrations were not associated with pregnancy potential in our study cohort (Fig. 1) . As a next step, we evaluated the influence of total androgen concentrations on pregnancy potential according to the FMR1 genotype (normal versus abnormal FMR1 genotype). Total androgen concentrations were not associated with pregnancy in women with the normal FMR1 genotype. In women with abnormal FMR1 findings, androgen concentrations at baseline and during work-up did not show a significant association with pregnancy.
At the start of the cycle, however, total T (b ¼ 0.257, SE + 0.098, P ¼ 0.009) and free T (b ¼ 1.199, SE + 0.504, P ¼ 0.017) affected clinical pregnancy potential among women with abnormal FMR1 genotypes. When corrected for age, duration of DHEA supplementation and oocyte yield, the impact of free T on clinical pregnancy potential remained significant (b ¼ 1.101, SE + 0.508, P ¼ 0.03), while both DHEA (b ¼ 20.414, SE + 0.227, P ¼ 0.068) and total T (b ¼ 0.497, SE + 0.268, P ¼ 0.064) almost reached statistical significance (Fig. 2) .
As a next step, the interactions of DHEA with DHEA-S, total and free T with regard to pregnancy potential were analyzed in the whole cohort. Androgen interactions at baseline and during work-up did not affect pregnancy rates. At the start of the cycle, however, androgen interactions between DHEA levels and total T (b ¼ 2 0.052, SE + 0.021, P ¼ 0.012) and between DHEA and free T (b ¼ 2 0.375, SE + 0.153, P ¼ 0.014) significantly affect pregnancy rates. These interactions between DHEA and total T (b ¼ 2 0.058, SE + 0.023, P ¼ 0.010) and between DHEA and free T (b ¼ 2 0.496, SE + 0.197, P ¼ 0.012) remained significant when adjusted for length of DHEA supplementation in weeks, age and oocyte yield. When the interactions between DHEA and total T (b ¼ 2 0.053, S.E. + 0.024, P ¼ 0.025) and between DHEA and free T at the start of the cycle (b ¼ 2 0.577, S.E. + 0.253, P ¼ 0.023) were then adjusted for age, duration on DHEA, oocyte yield and, additionally, for embryos transferred, they still affected clinical pregnancy odds. When these analyses were repeated for FMR1, no significant impact of androgen interactions on pregnancy was observed.
To ensure that the observed effects were the consequence of DHEA supplementation, we created an interaction term between total and free T as continuous variables and DHEA as a bivariate, with one state representing the normal physiologic state and the other representing the anticipated DHEA levels in the presence of supplementation. (i.e. levels above the upper limit of normal). This analysis confirmed the effects of DHEA supplementation by demonstrating that, in the presence of supraphysiologic levels of DHEA, incremental increases of total and free T, independently, increased the odds of pregnancy (total T by a factor of 1.18, P ¼ 0.012; free T by a factor of 6.65 P ¼ 0.007).
Discussion
Our results demonstrate significant effects of androgen metabolization on pregnancy rates in women with POA, after supplementation with DHEA. Women, who are unable to effectively convert DHEA into DHEA-S and, consequently, testosterone experience significantly lower pregnancy chances than those with quick rises in DHEA-S and testosterone levels (Fig. 1) . If androgen metabolization is, as our results suggest, important for proper follicular growth, women with higher testosterone concentrations should experience better pregnancy chances. Though recent meta-analyses on testosterone co-treatment in women with POA are supportive (Sunkara and Coomarasamy, 2011; Bosdou et al., 2012) , the discussion on whether androgen supplementation in poor responders may or may not be beneficial remains controversial (Massin et al., 2006; Kim et al., 2011) . Our previous findings and the here presented results may shed further light on this issue. Pregnancy rates were not associated with absolute testosterone levels in our whole cohort; however in women with abnormal FMR1 genotypes, those with increased testosterone concentrations at the start of the cycle demonstrated significantly higher pregnancy potential. These results remained significant when controlled for confounding factors, such as female age, oocyte numbers, embryos transferred and duration of DHEA supplementation. To ensure that the association between higher testosterone concentrations and improved pregnancy rates were the consequence of DHEA supplementation, we could demonstrate that incremental increases in total and free T, independently, increased odds of pregnancy in women with supraphysiologic levels of DHEA.
As Fig. 2 demonstrates, women with abnormal FMR1 genotypes who conceived, started treatment with lower testosterone levels, but by the start of the IVF cycle had reached higher levels than women who failed to establish pregnancy. These findings correspond to our previous reports on selective effectiveness of DHEA supplementation (Gleicher et al., 2010a,b,c,d) . They are also in accordance with data by Qin et al. (2011) , who recently reported lower pregnancy rates in POA patients with low serum testosterone levels. Testosterone concentrations, however, did not affect cycle outcomes in women with normal ovarian response (Heijnen et al., 2006) .
The data presented here regarding POA patients, thus, suggest the significance of androgens for follicle maturation in humans. They support the assumption that both, androgen metabolization and absolute androgen concentrations matter in women with POA. Women with abnormal FMR1 genotypes, who conceived had low androgen levels at presentation but the highest levels by the start of the IVF cycle (Fig. 1) . They, therefore, have, possibly due to genetically determined deficiency of substrates for androgen production, the largest need for androgen supplementation. Once androgen deficiency is eliminated, their ability to metabolize DHEA into testosterone significantly improves their pregnancy chances. In contrast, the pregnancy potential in women with normal FMR1 genotypes does not appear related to absolute testosterone concentrations. Why that is remains to be determined. One possible explanation could be that the normal FMR1 genotype is inherently associated with higher testosterone/androgen levels than abnormal genotypes.
If confirmed, one can hypothesize a minimum androgen threshold, and possible therapeutic range, for sustained follicle development that was only reached in women with the normal FMR1 genotype. Such a range may be flexible, as we previously proposed as a general principle for hormonal activities (Weghofer and Gleicher, 2009 ). Within such a context, one may also presume that too high androgen levels, as in PCOS, may cause adverse effects on follicle maturation (Gleicher et al., 2011a,b,c) .
The concept of a therapeutic range of androgen concentrations suggests that proper 'ovarian microenvironments' are essential for follicular recruitment and growth. Since follicular recruitment takes place weeks before ovulation, it is tempting to speculate that such microenvironments may, indeed, become particularly important at the preantral and antral stage. Such a timeline corresponds well to the androgen-receptiveness of small pre-antral and early antral follicles, observed in animal models (Aerts and Bols, 2010; Sen and Hammes, 2010) and may also explain why beneficial DHEA effects on pregnancy were only apparent at the start of the IVF cycle, after weeks of DHEA supplementation (Gleicher et al., 2010a,b,c,d; Wiser et al., 2010) .
Restoration of negatively affected 'microenvironments' to better health, for example via DHEA supplementation, may as we previously suggested (Gleicher et al., 2011a,b,c) , at least partially, reverse selective effects of the POA process. It would be tempting to speculate that women who are capable of establishing such a microenvironment may experience higher pregnancy chances. Though the causative factors for these findings remain to be elucidated, IVF patients with a normal FMR1 genotype, indeed, experience higher pregnancy rates when compared with their counterparts with abnormal FMR1 genotypes and subgenotypes (Gleicher et al., 2011a,b,c) .
If androgens have, indeed, such an impact on pregnancy potential in women with POA, as our data and other reports suggest (Qin et al., 2011) , one may interpret absolute androgen deficiency as a defining characteristic of POA that may be genetically linked to abnormal FMR1 genotypes. Such an explanation would then suggest varying phenotypical profiles in women with POA, depending on FMR1 genotype, and a functional association between the FMR1 gene and androgen metabolism.
Classical features of PCOS, such as hyperandrogenism and high excessive antral follicle counts (Dewailly et al., 2010) , could consequently be seen as a contrary analogy to the hypo-androgenic and normo-androgenic phenotypes of POA we have observed. Though the fact that a subgroup of women showed additional diagnostic factors, such as PCOS, may be seen as a limitation of the study and though this PCOS subgroup was too small (n ¼ 7) to draw definite conclusions, the observed trend towards higher AMH and androgen concentrations in these women supports this concept.
In conclusion, our results suggest an essential role for androgens in folliculogenesis and establishment of pregnancy in infertile women with POA. DHEA supplementation appears to facilitate restoration of androgenic ovarian endocrine microenvironments, which positively influence pregnancy chances with IVF. Clinical effectiveness, however, varies with FMR1 genotypes. As hyper-androgenism is seen as a characteristic feature of PCOS (Dewailly et al., 2010) , hypo-androgenism may be viewed as a feature of POA, characterized by ovarian FMR1 genotypes.
